Search Results - "KENDALL, David M"

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study by Drucker, Daniel J, Dr, Buse, John B, MD, Taylor, Kristin, PhD, Kendall, David M, MD, Trautmann, Michael, MD, Zhuang, Dongliang, PhD, Porter, Lisa, MD

“…Summary Background Exenatide is an incretin mimetic that shares glucoregulatory properties with glucagon-like peptide 1 (GLP-1), and improves glycaemic…”
Get full text

Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children by Thornton, Paul S, De Leon, Diva D, Empting, Susann, Zangen, David, Kendall, David M, Birch, Sune, Bøge, Eva, Ivkovic, Jelena, Banerjee, Indraneel

“…Abstract Context Congenital hyperinsulinism (CHI) is characterized by dysregulated insulin secretion causing hypoglycemia and consequent brain damage…”
Get full text

Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families by Banerjee, Indraneel, Raskin, Julie, Arnoux, Jean-Baptiste, De Leon, Diva D, Weinzimer, Stuart A, Hammer, Mette, Kendall, David M, Thornton, Paul S

“…Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in infants and children, and carries a considerable risk of neurological…”
Get full text

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea by Kendall, David M, Riddle, Matthew C, Rosenstock, Julio, Zhuang, Dongliang, Kim, Dennis D, Fineman, Mark S, Baron, Alain D

“…OBJECTIVE:--This study evaluated the effects of exenatide, a novel incretin mimetic, in hyperglycemic patients with type 2 diabetes unable to achieve glycemic…”
Get full text

Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use by Kendall, David M., MD, Cuddihy, Robert M., MD, Bergenstal, Richard M., MD

“…Abstract Incretin-based therapies address the progressive nature of type 2 diabetes mellitus, not only by addressing glucose control but also with…”
Get full text

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial by Barnett, Anthony H., MD, Burger, Jude, MS, Johns, Don, PhD, Brodows, Robert, MD, Kendall, David M., MD, Roberts, Anthony, MD, Trautmann, Michael E., MD

“…Abstract Objective: This study was conducted to compare the efficacy and safety profiles of exenatide and insulin glargine therapy in patients with type 2…”
Get full text

Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia by Goldberg, Ronald B, Kendall, David M, Deeg, Mark A, Buse, John B, Zagar, Anthony J, Pinaire, Jane A, Tan, Meng H, Khan, Mehmood A, Perez, Alfonso T, Jacober, Scott J

“…OBJECTIVE:--Published reports suggest that pioglitazone and rosiglitazone have different effects on lipids in patients with type 2 diabetes. However, these…”
Get full text

Correction to: Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families by Banerjee, Indraneel, Raskin, Julie, Arnoux, Jean-Baptiste, De Leon, Diva D, Weinzimer, Stuart A, Hammer, Mette, Kendall, David M, Thornton, Paul S

“…Congenital hyperinsulinism (CHI) is a rare disease that causes newborn babies and children to have low blood sugar because of the abnormal release of insulin…”
Get full text

Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia by Deeg, Mark A, Buse, John B, Goldberg, Ronald B, Kendall, David M, Zagar, Anthony J, Jacober, Scott J, Khan, Mehmood A, Perez, Alfonzo T, Tan, Meng H

“…OBJECTIVE:--Associated with insulin resistance in type 2 diabetes are increased serum triglycerides, decreased HDL cholesterol, and a predominance of large…”
Get full text

Glycemia Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial by Gerstein, Hertzel C., MD, MSc, Riddle, Matthew C., MD, Kendall, David M., MD, Cohen, Robert M., MD, Goland, Robin, MD, Feinglos, Mark N., MD, CM, Kirk, Julienne K., PharmD, CDE, Hamilton, Bruce P., MD, Ismail-Beigi, Faramarz, MD, PhD, Feeney, Patricia, MS, MA

“…There is an independent progressive epidemiologic relation between glycemia and cardiovascular disease (CVD) events; however, whether lowering glucose levels…”
Get full text

Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications by Bergenstal, Richard M., MD, Bailey, Clifford J., PhD, Kendall, David M., MD

“…Abstract The selection of appropriate pharmacologic therapy for any disease requires a careful assessment of benefit and risk. In the case of type 2 diabetes,…”
Get full text

Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis by Ascher-Svanum, Haya, Zagar, Anthony, Jiang, Dingfeng, Schuster, Dara, Schmitt, Henry, Dennehy, Ellen B., Kendall, David M., Raskin, Joel, Heine, Robert J.

“…Introduction Although depression is often associated with poor glycemic control in patients with type 2 diabetes mellitus (T2DM), this observation has been…”
Get full text

Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use by Kendall, David M., MD, Cuddihy, Robert M., MD, Bergenstal, Richard M., MD

“…Abstract Incretin-based therapies address the progressive nature of type 2 diabetes mellitus, not only by addressing glucose control but also with…”
Get full text

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis by Fu, Haoda, Cao, Dachuang, Boye, Kristina S., Curtis, Bradley, Schuster, Dara L., Kendall, David M., Ascher-Svanum, Haya

“…Introduction American Diabetes Association consensus guidelines emphasize individualized treatment in the management of type 2 diabetes mellitus (T2DM). Early…”
Get full text

A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia by Bailey, Naila Celeste, Dimsits, Jeannett, Hammer, Mette, Kendall, David M, Bailey, Timothy S

“…Severe hypoglycemic episodes are life-threatening events demanding rapid administration of glucagon by a caregiver or bystander. The glucagon analog…”
Get more information

Prevention of Diabetes for up to 13 Years by Autoislet Transplantation After Pancreatectomy for Chronic Pancreatitis by ROBERTSON, R. Paul, LANZ, Karla J, SUTHERLAND, David E. R, KENDALL, David M

“…Prevention of Diabetes for up to 13 Years by Autoislet Transplantation After Pancreatectomy for Chronic Pancreatitis R. Paul Robertson , Karla J. Lanz , David…”
Get full text

1024-P: Technosphere Insulin Added to Basal Insulin Is Associated with Less Weight Gain than Basal Insulin plus Insulin Aspart or Insulin Analog (Aspart) 70/30 Mixture in Type 2 DM by MANOUKIAN, JONATHAN, KENDALL, DAVID M., MOREY, PATRICK M., HOOGWERF, BYRON J.

“…Technosphere Insulin (TI) is a dry-powder formulation of recombinant human insulin adsorbed onto Technosphere microparticles for oral inhalation. Data from two…”
Get full text

137-OR: Dasiglucagon Ready-to-Use Autoinjector Is More Reliably and Quickly Administered than Glucagon Emergency Kit (GEK) by BAILEY, N. CELESTE, DIMSITS, JEANNETT, TEHRANCHI, RAMIN, KENDALL, DAVID M., BAILEY, TIMOTHY S.

“…Dasiglucagon is a novel glucagon analog, stable in aqueous solution and suitable for delivery in a ready-to-use autoinjector (HypoPal®) for the treatment of…”
Get full text

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial by Bunck, Mathijs C, Diamant, Michaela, Cornér, Anja, Eliasson, Bjorn, Malloy, Jaret L, Shaginian, Rimma M, Deng, Wei, Kendall, David M, Taskinen, Marja-Riitta, Smith, Ulf, Yki-Järvinen, Hannele, Heine, Robert J

“…OBJECTIVE: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with…”
Get full text

RESULTS OF A 24-WEEK TRIAL OF TECHNOSPHERE INSULIN VERSUS INSULIN ASPART IN TYPE 2 DIABETES by Hoogwerf, Byron J, Pantalone, Kevin M, Basina, Marina, Jones, Marisa C, Grant, Marshall, Kendall, David M

“…To compare glycemic efficacy of Technosphere insulin (TI) versus that of insulin aspart (IA), each added to basal insulin, in type 2 diabetes. This randomized,…”
Get more information